Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evusheld

- PMLiVE

AZ strikes antibiotic deal with Singapore research unit

Deal with A*STAR to tackle antimicrobial resistance

- PMLiVE

AZ names Dunoyer as CFO

He succeeds Simon Lowth as company restructure continues apace

- PMLiVE

AZ takes severe asthma antibody into phase III

Benralizumab shows promise in clinical trials

- PMLiVE

Novartis’ Lucentis wins fourth NICE recommendation

But eye drug only recommended after a price-cutting patient access scheme offered

- PMLiVE

AstraZeneca to close UK environmental lab

Decision on Brixham facility in Devon puts 71 positions at risk

- PMLiVE

Celgene’s Revlimid knocked-back by NICE

Final draft guidance from NICE does not recommend drug for rare bone marrow disorder

Novartis building

NICE backs Novartis/ ThromboGenics’ eye drug

Recommends Jetrea for NHS use in England and Wales to treat the rare disease vitreomacular traction

- PMLiVE

AstraZeneca moves MEK inhibitor selumetinib into phase III

Begins late-stage trials of its targeted lung cancer drug

- PMLiVE

Astellas wins NICE backing for Xtandi in prostate cancer

England’s health guidance body says drug can be used in advanced cases of the disease

- PMLiVE

AZ buys into ADC sector with $440m Spirogen deal

Pushes into the market for antibody-drug conjugates

- PMLiVE

NICE unmoved by Pixuvri access scheme

England’s HTA body once again denies Cell Therapeutics' blood cancer treatment

- PMLiVE

AstraZeneca/J&J form Japanese cancer partnership

Two companies will co-promote Zytiga in prostate cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links